NCT06971237 - SIRT and Peri-immunotherapy : a New Concept | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy

Interventions

DRUG

Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization

"Atezolizumab ± Bevacizumab: Peri-immunotherapy with , with or without bevacizumab, given before and after SIRT.~\- Yttrium-90 Radioembolization: Selective Internal Radiation Therapy (SIRT) via intra-arterial injection of Yttrium-90 microspheres for liver tumor control"

DRUG

Atezolizumab ± Bevacizumab

Standard systemic immunotherapy administered without SIRT, using atezolizumab with or without bevacizumab.

Trial Locations (1)

94800

Hôpital Paul Brousse - Radiology Department, Villejuif

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER